News & Blog

Read the latest business news, blogs and thought leadership articles from our members, as well as updates on the Edinburgh Chamber of Commerce's work in the city.

News & Blog

Randox Health to introduce a Prostate Cancer Risk test, panel, and Algorithm

Posted: 2nd November 2023

Randox Health are celebrating Men’s Health Month with the launch of a new Prostate Cancer Risk test, this November.

In the UK, one in every eight men will be diagnosed with prostate cancer within their lifetime, making it the most common form of cancer in men, usually affecting those over the age of 50.

Almost 50,000 men in the United Kingdom are diagnosed each year with prostate cancer. It is estimated that 12,000 men die every year from prostate cancer, that’s one death every 45 minutes.

Randox Health have a proactive approach to health and have developed a new Prostate Cancer Risk testing panel. The aim of which, is to stratify risk and triage patients into those who may be ‘high’ risk and those who are more likely ‘low’ risk.

Traditionally, PSA (Prostate Specific Antigen) testing is mainly used to screen for prostate cancer, PSA measures the level of Prostate Specific Antigen in the blood and can indicate abnormality within the prostate. PSA is a protein produced by cells of the prostate gland. These levels tend to increase with age as the size of the prostate increases.

Although PSA is highly specific for prostate disease, it is not specific for prostate cancer. A raised PSA can also indicate an enlarged prostate, prostatitis, or a urinary tract infection.

The new Randox Health testing panel includes PSA testing, as well as analysis of a novel combination of biomarkers to calculate a prostate cancer risk score. The inclusion of the additional biomarkers, and the employment of the algorithm allows for more accurate risk stratification helping to reduce the need for unnecessary, invasive further investigations in low-risk individuals.

Attributable Quotes:

Dr. Mark Ruddock BSc PhD, Chief Scientific Officer (CSO), Randox Health.

Our revolutionary prostate cancer risk prediction test not only identifies individuals at elevated risk, directing them to specialised care for timely intervention, but it also provides assurance to those at lower risk, sparing them unnecessary invasive procedures.

“Harnessing the power of tailored risk assessment, we navigate the path to proactive healthcare, ensuring that each man’s journey is as unique as his well-being.”

About Randox Health

Established in 1982, Randox is the largest healthcare diagnostics company from the UK & Ireland. Randox focusses on the provisional of timely and accurate testing to identify risks to health, improve clinical diagnosis and promote preventative healthcare; aiming to achieve to achieve better healthcare outcomes, whilst reducing the burden on clinical services. Randox Health Clinics are based throughout the UK & Ireland, enabling easy-access for millions of people to a new range of preventative health packages designed to help clients take control of their health.

For more information, please visit: www.randoxhealth.com

Business Comment

Business Comment is the Edinburgh Chamber of Commerce’s bi-monthly magazine. It provides insight on Edinburgh’s vibrant business community, with features on the city’s key sectors, interviews with leading figures and news on new business developments in the capital.
Read more here